Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MYLAN HAS FIRST GENERIC VERSION OF BOEHRINGER-INGELHEIM's COMBIPRES

Executive Summary

MYLAN HAS FIRST GENERIC VERSION OF BOEHRINGER-INGELHEIM's COMBIPRES (clonidine/chlorthalidone); the generic company began marketing the combination product during the week following ANDA approval of the drug on Feb. 9. Mylan estimated the current market for the brandname drug at approximately $17-18 mil. annually, based on IMS data. Mylan is marketing the generic at an average wholesale price of $23.35 for 100 capsules of .1 mg clonidine/15 mg chlorthalidone; $31.20 for 100 capsules of .2 mg clonidine/15 mg chlorthalidone; and $37.70 for 100 capsules of .3 mg clonidine/15 mg chlorthalidone. Generic versions of clonidine (Boehringer-Ingelheim's Catapres) have been available since July 1986, when the patent on Catapres expired. Mylan indicated that it has plans to market generic clonidine as well. In 1986, Mylan received first generic approvals for five products. Of those, the firm received a same day approval for haloperidol with Searle (June 10) and with Barr for chlordiazepoxide/amitriptyline HCl (Dec. 10). Mylan's remaining first approvals in 1986 were for doxepin HCl, meclofenamate sodium, and tolazamide. Mylan had four first approvals in 1985.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS011507

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel